- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 29, Issue 4, 2022
Current Medicinal Chemistry - Volume 29, Issue 4, 2022
Volume 29, Issue 4, 2022
-
-
Targeting Chikungunya Virus Entry: Alternatives for New Inhibitors in Drug Discovery
Chikungunya virus (CHIKV) is an Alphavirus (Togaviridae) responsible for Chikungunya fever (CHIKF) that is mainly characterized by a severe polyarthralgia, in which it is transmitted by the bite of infected Aedes aegypti and Ae. albopictus mosquitoes. Nowadays, there are no licensed vaccines or approved drugs to specifically treat this viral disease. Structural viral proteins participate in key steps of its replication cycle, Read More
-
-
-
Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy
Due to its fast international spread and substantial mortality, the coronavirus disease COVID-19 evolved to a global threat. Since there is currently no causative drug against this viral infection available, science is striving for new drugs and other approaches to treat the new disease. Studies have shown that the cell entry of coronaviruses into host cells takes place through the binding of the viral spike (S) protein to cell recept Read More
-
-
-
Structural Basis for the Understanding of Entry Inhibitors against SARS Viruses
Authors: Prem K. Kushwaha, Neha Kumari, Sneha Nayak, Keshav Kishor and Ashoke SharonOutbreaks due to Severe Acute Respiratory Syndrome-Corona virus 2 (SARSCoV- 2) initiated in Wuhan city, China, in December 2019 and continued to spread Internationally, posing a pandemic threat as declared by WHO and as of March 10, 2021, confirmed cases reached 118 million along with 2.6 million deaths worldwide. In the absence of specific antiviral medication, symptomatic treatment and physical isolation remain the o Read More
-
-
-
SARS-CoV-2 Entry Inhibitors Targeting Virus-ACE2 or Virus-TMPRSS2 Interactions
Authors: Hao Lin, Srinivasulu Cherukupalli, Da Feng, Shenghua Gao, Dongwei Kang, Peng Zhan and Xinyong LiuCOVID-19 is an infectious disease caused by SARS-CoV-2. The life cycle of SARS-CoV-2 includes the entry into the target cells, replicase translation, replicating and transcribing genomes, translating structural proteins, assembling and releasing new virions. Entering host cells is a crucial stage in the early life cycle of the virus, and blocking this stage can effectively prevent virus infection. SARS enters the target cells mediated by t Read More
-
-
-
Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins
Authors: Jing Pu, Joey T. Zhou, Ping Liu, Fei Yu, Xiaoyang He, Lu Lu and Shibo JiangType l enveloped viruses bind to cell receptors through surface glycoproteins to initiate infection or undergo receptor-mediated endocytosis and initiate membrane fusion in the acidic environment of endocytic compartments, releasing genetic material into the cell. In the process of membrane fusion, envelope protein exposes fusion peptide, followed by an insertion into the cell membrane or endosomal membrane. Read More
-
-
-
Challenges and Perspectives in the Discovery of Dengue Virus Entry Inhibitors
Authors: Facundo N. Gallo, Ana G. Enderle, Lucas A. Pardo, Emilse S. Leal and Mariela BolliniDengue virus (DENV) disease has become one of the major challenges in public health. Currently, there is no antiviral treatment for this infection. Since human transmission occurs via mosquitoes of the Aedes genus, most efforts have been focused on the control of this vector. However, these control strategies have not been totally successful, as reflected in the increasing number of DENV infections per year, becoming an end Read More
-
-
-
Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Authors: Merve Erkisa, Melda Sariman, Oyku G. Geyik, Caner Geyik, Tatjana Stanojkovic and Engin UlukayaCancer remains a deadly disease, and its treatment desperately needs to be managed through novel, rapidly advancing strategies. Most cancer cases eventually develop into recurrences, for which cancer stem cells (CSCs) are thought to be responsible. These cells are considered a subpopulation of all tumor cancer cells, with aberrant regulation of self-renewal, unbalanced proliferation, and cell death properties. CS Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
